Guideline 7.1 – Malignancy:
We suggest treating symptomatic anaemia in people with CKD and cancer when Hb <100 g/L. (2B)
Guideline 7.2 – Haematological Disease:
We suggest ESA therapy be considered in people with myelodysplastic syndrome (MDS), myeloma and others with CKD and haematological disease. We make no recommendations on HIF-PHI therapy. (not graded)
Guideline 7.3 – Pregnancy:
We recommend that pregnant and post-partum women with CKD are given parenteral iron, if indicated, from the second trimester onwards, if the benefit is judged to outweigh the potential risk for the mother and fetus and according to SmPC guidance. (1C)
Guideline 7.3.1
We recommend that ESA therapy during pregnancy be